Rosiglitazone: a European regulatory perspective. (Q34154718)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21153629%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

title

Rosiglitazone: a European regulatory perspective (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21153629%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21153629%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

K Dunder

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21153629%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

P A de Graeff

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21153629%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

E Abadie

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21153629%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

14 December 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21153629%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21153629%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

54

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21153629%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

213-218

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21153629%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21153629%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00125-010-1992-5

18 January 2020

exact match

0 references

cites work

Rosiglitazone: what went wrong?

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1992-5

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1992-5

Rosiglitazone--continued uncertainty about safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1992-5

Rosiglitazone and cardiotoxicity--weighing the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1992-5

Rosiglitazone RECORD study: glucose control outcomes at 18 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1992-5

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1992-5

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1992-5

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1992-5

Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1992-5

Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1992-5

Risk of cardiovascular events and all-cause mortality in patients treated with thiazolidinediones in a managed-care population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1992-5

Licensing drugs for diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1992-5

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1992-5

Patient-important outcomes in diabetes—time for consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1992-5

The record on rosiglitazone and the risk of myocardial infarction

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21153629

12 December 2020

inferred from PubMed ID database lookup

The rosiglitazone story--lessons from an FDA Advisory Committee meeting

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21153629

12 December 2020

inferred from PubMed ID database lookup

Rosiglitazone and cardiovascular risk

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21153629

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1007/S00125-010-1992-5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21153629%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

18 January 2020

1013882897

0 references

Fatcat ID

release_kgbjlgdzgvhi7cayan6o4nh4w4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/kgbjlgdzgvhi7cayan6o4nh4w4

24 November 2022

mapped directly with Wikidata item

1 reference